Afatinib
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-AFATINIB |
|---|---|
| Type | Drug |
| Aliases | GilotrifGiotrifАфатиніб |
| Status | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-NSCLC-METASTATIC-2024 SRC-NCCN-NSCLC-2025 |
Drug Facts
| Class | 2nd-generation EGFR/HER2 TKI (irreversible) |
|---|---|
| Mechanism | Irreversible pan-HER (EGFR / HER2 / HER4) TKI. More toxic than 1G TKIs but covers some uncommon EGFR mutations (G719X, L861Q, S768I). LUX-Lung 7 / 8: superior PFS vs gefitinib / erlotinib in selected populations. |
| Typical dosing | 40 mg PO once daily on empty stomach. Reduce to 30 mg if intolerable diarrhea. |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Notes
Niche use for uncommon EGFR mutations not covered by osimertinib. Rarely first-line in modern era.
Used By
No reverse references found in the YAML corpus.